A phase Ib study of patients with MET-positive CRC indicated that the treatment strategy of capmatinib in combination with cetuximab (an anti-EGFR monoclonal antibody) was tolerable and showed preliminary antitumor effects (Delord et al., 2020). Here, EGFR is linked to colorectal carcinoma.